Home » Newsletters » BioWorld Science

BioWorld Science

May 22, 2012

View Archived Issues

Research at Merck Frosst Canada yields new HIV protease inhibitors

Merck KGaA discloses new PI3K inhibitors

Long-term results with Lenti-D reported

Takeda reviews achievements of fiscal 2011

Researchers describe preclinical and phase I results with AQX-1125

Cardioprotection observed with novel bivalent engineered neuregulin 1B protein

Secretin relieves pain in chronic pancreatitis patients

Novel Anacor Pharmaceuticals compound reduces inflammation in vivo

DPT-NX7 induces regressions in squamous cell carcinoma model

Lupin designs new CRAC channel modulators

Novel Abeta production inhibitors created at Dainippon Sumitomo

FDA includes 156-week data in new Isentress labeling

Canadian universities develop novel antibiotics

Kinex out-licenses rights to KX-02 in greater China territory

Peregrine Pharmaceuticals reports data from phase IIb study in NSCLC

New iPierian programs target Tau protein and complement pathway

Oxford BioTherapeutics presents new diagnostic antibodies

Daiichi Sankyo and the Japanese National Cancer Center enter anticancer collaboration

Achillion reports new proof-of-concept data for ACH-2684

CHDI Foundation to conduct preclinical research on Lundbeck compound

Cerecor commences exploratory trial of FP-01

Phase III MISSION trial misses primary endpoint

Third phase III trial of Sativex in cancer pain begins

Medivation submits NDA for enzalutamide

Enrollment complete in phase I trial of MOR-208

Phase IIb trial of Catalyst's treatment candidate for cocaine addiction reaches target enrollment

Cellceutix gives update on IND for novel p53 anticancer drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...